Pretomanid Gets Panel Endorsement As Part Of Regimen, Not Individual Molecule, For Treatment-Resistant Tuberculosis

 
• By Michael Cipriano

US FDA's Antimicrobial Drugs Advisory Committee made clear that its positive 14-4 approval vote was supportive of the TB Alliance's pretomanid as part of a regimen for treatment-resistant tuberculosis since the role of each active ingredient in the combination is not adequately understood. 

FDA Advisory Committee Feature image
The Antimicrobial Drugs Advisory Committee voted 14-4 supporting approval of the pretomanid regimen.

More from US FDA Performance Tracker

More from Regulatory Trackers